Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cells and drugs injected directly into brain tumor in new trial

NCT ID NCT03233152

Ongoing Disease control Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase I/II trial tests a combination of immune cells (dendritic cells) and two immunotherapy drugs (ipilimumab and nivolumab) for people with recurrent glioblastoma, an aggressive brain cancer. The treatment is given directly into the tumor during surgery, followed by more doses into the brain cavity and vein. The goal is to see if this approach can improve survival without causing severe side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dendritic cells (immune cells) plus ipilimumab and nivolumab (immunotherapy drugs)
What this could lead to
If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with very few effective therapies.
What could go wrong
This is an early-phase trial (phase I/II) with only 110 participants, so results may not apply to all patients. The treatment involves brain injections and carries risks like immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

  • Universitair Ziekenhuis Brussel

    Brussels, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.